Swedish medtech company Amferia, a developer of next-generation antimicrobial wound-care solutions, announced that it has closed an oversubscribed EUR3.5m investment round.

The funding was led by existing shareholders alongside new investors active in global wound care.

The capital will support clinical development in human health, scale the company's animal-health business and advance commercialisation of products based on its proprietary antimicrobial peptide hydrogel platform. Amferia plans to progress towards CE marking in Europe and FDA clearance in the United States, while expanding animal-health operations in Europe, where it has commercial agreements with Orkla Wound Care AB and Biokema SA.

During the past year, Amferia launched Europe's first veterinary wound dressing using antimicrobial peptides and advanced its US regulatory pathway for human wound care. The company's hydrogel technology is designed to stabilise antimicrobial peptides to kill bacteria, including antibiotic-resistant strains, without damaging surrounding tissue. Amferia said that research shows that combining the hydrogel with antibiotics can increase bactericidal effect by up to 64 times.

Amferia is developing applications across human and veterinary care, including wound dressings, post-operative and chronic wound care, trauma and burn treatments, surgical materials, and antimicrobial coatings for implants and medical devices.